- ICH GCP
- Registre des essais cliniques de l'UE
Derniers essais
EudraCT Number: 2022-001393-58 | Sponsor Protocol Number: T21-118 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Hagaziekenhuis | ||||||||
Full Title: POMPAE trial: Peri-Operative Magnesium infusion to Prevent Atrial fibrillation Evaluated. | ||||||||
Medical condition: Atrial fibrillation | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001297-63 | Sponsor Protocol Number: ML-ORI-201 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Melinta Therapeutics, LLC | ||||||||
Full Title: A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin Versus Standard of Care for the Treatment of Pediatric Subjects... | ||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infections | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: BG (Ongoing) LT (Ongoing) LV (Ongoing) PL (Ongoing) ES (Ongoing) PT (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003065-38 | Sponsor Protocol Number: 1102-DMD-Pre-CT03 | Start Date: 2023-04-13 | |||||||||||
Sponsor Name: Antisense Therapeutics Limited | |||||||||||||
Full Title: A multicentre, randomised, double-blind, placebo-controlled and open label extension study to assess the efficacy, safety, and pharmacokinetic profile of two dose levels of ATL1102 administered by ... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002524-12 | Sponsor Protocol Number: BNZ-20-01-2022 | Start Date: 2023-04-13 | ||||||
Sponsor Name: AZAD Pharma AG | ||||||||
Full Title: A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Br... | ||||||||
Medical condition: GLAUCOMA , OCCULAR HYPERTENSION | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: BG (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002014-16 | Sponsor Protocol Number: VIR-MHB1-V200 | Start Date: 2023-04-12 | |||||||||||
Sponsor Name: Vir Biotechnology, Inc. | |||||||||||||
Full Title: A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL) | |||||||||||||
Medical condition: Chronic Hepatitis B Virus (HBV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002751-19 | Sponsor Protocol Number: 82160 | Start Date: 2023-04-11 | ||||||
Sponsor Name: Amsterdam UMC | ||||||||
Full Title: FAPi-PET imaging of in vivo fibrosis in inflammatory bowel disease patients | ||||||||
Medical condition: Inflammatory Bowel Diseases | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002746-40 | Sponsor Protocol Number: VX22-864-108 | Start Date: 2023-04-11 | |||||||||||
Sponsor Name: Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks | |||||||||||||
Medical condition: Alpha 1 antitrypsin deficiency in Subjects With the PiZZ Genotype | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002965-13 | Sponsor Protocol Number: TAK-861-2003 | Start Date: 2023-04-11 | |||||||||||
Sponsor Name: Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions | |||||||||||||
Medical condition: Narcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) SE (Ongoing) FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001189-40 | Sponsor Protocol Number: APD811-303 | Start Date: 2023-04-05 | |||||||||||
Sponsor Name: Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION | |||||||||||||
Medical condition: Pulmonary arterial hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) CZ (Ongoing) BE (Ongoing) DK (Ongoing) NL (Ongoing) HU (Ongoing) BG (Ongoing) GR (Ongoing) PL (Ongoing) PT (Ongoing) HR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001547-25 | Sponsor Protocol Number: ZILO-301 | Start Date: 2023-04-04 | |||||||||||||||||||||
Sponsor Name: Oncternal Therapeutics, Inc | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects with Relapsed or Refractory Ma... | |||||||||||||||||||||||
Medical condition: Relapsed or Refractory Mantle Cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |